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Table 1. Clinical Characteristics of the 36 Study Patients 
n Age [YIil 
NO. Gender ECMP 
IHD 0.25 IO _ Am, SP 
PDC 0.20 Itxl c 75 
E-ID 0.25 75 - Nil 
AIC 0.2s 50 E to 
MD 0.20 125 - Am. Nit 
IHD 0.25 75 c so - 
A6 0.25 50 ES SP 
IHD - 75 C50 
IHD - 125 sp- 
AL 0.25 50 - - 
PDC _ ?5 E IO Nit 
PDC “.Zil 25 Nil 
PDC 0.20 50 
PDC 0.25 50 c 75 
PDC 0 25 125 E 2.5 sp 
PDC 25 - - 
PDC 0.x 75 _ Am 
PDC 0.25 Xl SP 
Group B kantral group wilhout ultrafilrratbn) 
I MUM IHD 0.20 50 _ _ 
2 71,F P”C 0.25 I!5 E 16 Am 
3 Q&l 1HD 0.25 25 E III 
4 57/M PDC 0.25 25 _ WiY 
5 59iM Ale 0.25 75 c 75 Nit 
6 WM Ak 0.25 I25 Am. sp 
1 6liM KID 0.20 25 - SP 
8 66/F PDC 0.25 25 - _ 
9 74JM IHD 0.20 50 E IO _ 
IO MM PDC - 25 E 20 Am 
II SUF PDC 0.25 75 c 50 
12 WM PLK 0.25 SD - - 
I3 WF PK 0.20 50 - SP 
I4 s81M IWD 0.25 50 Nil 
15 63lM PDC 0.20 IW CW Am, Nit 
16 6E.w PDC 0.25 2.5 E 10 _ 
I? JliM PM 0.25 2M c 75 Am 
I8 JYM PDC 0.20 59 c 50 Nit 
AC&h = angiolcnsin-converling enzyme inhibilors: Ak = &oh&: Am = amiodarone: C = caplopnl: DcMp = dilated Wrdj~YopstbY Ctidogy; E = 
enalapd: F = female; IHD = ischemic hean disease; M = male: Nit = nitrates: PDC = priman dilated wdbmyopathy; R = patie!& SP = SPiWWkslO~. 
pectoris. primary valvular heart disease, intermittent claudi- 
cation, fibrotic or primary vascalar ltmg diseases, simts or 
atrioventricular node dysfunction, etkt-induced severe 
ventricular arrhythmias or an artifxhd pacemaker were 
excluded. The study protocol was approved by the local 
Ethics Committee. Ail patients gave informed written con- 
sent after receiving detailed infomtation concerning the 
procedures, possible clinical benefits and investigative pur- 
poses. They were randomly divided into grtmps A and B, 
each consisting of I8 patients. Ultraliltration was performed 
in group A; subjects in group B served as the control group. 
DBralittraticat. In each patient in group A, a single uhra- 
Itration procedure was performed dming temporary admis- 
sion to the intensive care tmit. A 7F triple-lumen thermndi- 
lution Swan-Canz catheter was percutaneousIy introduced 
into an antecnbital or jugular vein and advanced to the 
pulmonary artery or wedge position when necessary. Stable 
hemodynamic onditions were achieved within 30 min after 
completion of the invasive procedures. Uiba8itmtion meth- 
ods have been pre4iously described in detail (3). In brief, a 
DZOSF r4micon diaiilter, whiih aiiows subtraction of water 
and sohnes of <SO,OMl daltons from blood, was inserted into 
a venovenoos bypass circuit (double-lumen Y-shaped cath- 
eter in a femoral vein). Blood was propetted through the 
diafdter by a Gambro System peristaltic pump AK10 (model 
BMM IC-IK) regulated to generate 603 ml/h of ukfdtrate. 
During ultratilbation, we continuously monitored rig&I atrim 
and pulmonary artery pressures. UltratItration was contin- 
ued until right atria1 pressure, measured at end-expiration. session by three independent experts who had no knowledge 
decreased by 50% of the baseline value. In group B patients, of the study protocol (26). 
the hemodynamic evaluation, but not ultrafiltration, was Plasma norepinephrine evaluations. Circulating norepi- 
performed. The day of the hemodynamic evaluation with nephrine was measured by high pelformance liquid chroma- 
(group A) and without (group B) ultratItration was consid- tography (27). Baseline determinations were made on blood 
ered day 0 of the study protocol. samples obtained 30 min after introduction of a catheter 
Pulmontwy and cardiac evaluations. We utilized a ches: (18G) into an antecubital or forearm vein with the patient in 
X-my scoring approach For extravascular lung water deter- the supine position. We also evaluated norepiaeptine kinet- 
mination (20); pulmonary function tests included a bron- its during exercise and onhostatic tilt. Blood was withdrawn 
chodilator response evaluation (salbutamol inhalation). at rest (with the patient upright after a mouthpiece had been 
Maximal voluntary ventilation was assessed as the greater of in position For 23 min), immediately before each work load 
that measured (60 to 70 breathslmin for 15 s) and that increment and at peak exercise. During the orthostatic tilt 
predicted from forced expiratoty volume (1 s) x 40 (21). The test, blood samples were obtained aFter 20 min of rest with 
prediction equation of Morris et al. (22) was used to deter- the patient supine and after a IO-min 60” head-up tilt. The 
mine forced expiratory volume. Cardiac dimensions were orthostatic tilt test was performed in both groups at days -I, 
measured by echocardiography (model 77020/A, Hewlett- 4 and 90. 
Packard). Ejection fraction was calculated by the formula of Slalisllcal analysis. Data are reported as mean values I 
Teichholz et al. (23). The values reported are the mean of 3 SEM. Data were analyzed by two-way analysis of variance 
consecutive beats (the mean of 10 beats was utilized when and differences from measorements done at day -1 versus 
atrial fibrillation occurred). Physical performance was eval- days 4, 30, 90 and 180 were evaluated by paired Student I 
uated through cardiopulmonary exercise tests that were test, applying the BonFerroni method because multiple com- 
performed in the upright position, on a cycloergometer 
parisons were made (28). Norepinephrine responses to or- 
(Collins Pedalmate), with 30 s of unloaded pedaling, Fol- thostatic tilt were assessed as a percent, using supine mea- 
lowed by 25-W increments every 3 min until the appearance 
surements as the baseline values. The immediate efFects of 
oF limiting dyspnea or Fatigue. Expiratory gases were col- 
ultrafiltration on hemodynamic variables were analyzed by 
lected on a breath by breath basis (MMC 4400, Sensor 
paired f test. We utilized the SPSs/pc+ Advanced Statistics 
Metlies). All patients were previously trained to perform the 
VZ.0 program. 
exercise test in our laboratory. Anaerobic threshold and 
peak oxygen consumption were determined according to Results 
standard methods (24). Oxygen consumption at anaerobic 
threshold and peak exercise are expressed as oxygen con- 
According to the criteria of the New York Heart Associ- 
sumption (mUmin per kg) during the 30 s in which an 
ation, 5 and I3 patients in group A and 6 and It in group B 
examined event occurred. Oxygen consumption values at 
were in functional classes II and 111, respectively. According 
each work load are the average of measurements obtained in 
to the heart failure sevnrity ranking proposed by Weberet al. 
the 30 s immediately preceding each increase in work load. 
(29). among patients in group A, 3 were in functional class A 
The reported maximal ventilation, tidal volume and dead 
(maximal oxygen consumption >20 mUmin per kg), 4 in class 
B (>I6 to 20 mUmin per kg), IO in class C (IO to I6 mUmin 
space/tidal volume ratioat peak exercise were averaged over 
30 s. The dead space/tidal volume ratio was derived accord. 
per kg) and I in dass D (<IO mUmin per kgl; amoog ;hose ir! 
ing to the method of Jones (25). We also utilized the 
group B, 4,4 and 10 were in class A, B and C, respectively. 
There were six cases (two in group A and four in group B) of 
prediction equation of that investigation (25) to determine chronic atrial fibrillation. Left ventricular ejection fraction 
maximal ventilation and dead space/tidal volume ratio at averaged 23.8 + 2.1% in group A and 24.1 f 1.8% in group 
peak exercise. Oxygen pulse at peak exercise was calculated B at day -I (Table 2). The two groups were also homage 
as peak oxygen consumption/peak heart rate. neous regarding baseline cardiac index and right atrial and 
Protocol. All patients were subjected to the same proce. 
dures, except that ukrafiltration was p&ormed only in 
pulmonary wedge pressure. The volume of ultrafiltrate av- 
eraged 1,884 f 174 ml (duration of ulttmiltration 18% 2 
group A. Patients were hospitalized during a run-in (Tday) 8 min). No side effects or symptoms were reported during 
period and the first 4 days of the follow.up evaluation. The the procedure. At the end of the procedure, rest mean right 
run-in period was utilized to confirm that the patient was in atrial pressure, mean pulmonary wedge pressure and cardiac 
a stable clinical condition. Patients were followed-up for 6 index were reduced from 8 f I io 3.4 + 0.7 mm Hg (p < 
months and the drug regimen was kept constant during this O.OOl), from LB + 2.5 to IO + 1.9 mm Hg @ < O.OO!) and 
period. Cardiopulmonary exercise tests were performed at from 2.8 f 0.2 to 2.3 ? 0.2 literslmin per m2 (p =Z O.Ol), 
10 AM on days -I, 4, 30, 90 and 180. Chest X-ray films, respectivety; mean blood pressure was unchanged (From 
pulmonary Function tests and echocardiograms wore ob- 85.5 + 2.5 to 83.5 t- 3.1 mm Hg) and total peripheral 
tained at the same periods. Results for each patient were resistance increased (from 1.221 f 45 to 1,632 ? 
analyzed at the end of the follow-up period during the same 1 I9 dyne~s~cm-s, p < 0.01). In group B, right atrial pres- 









vrnutcular diajtaik dlametcr. 
sure. mean pulmonary wedge pressure and cardiac index at 
rest were 7.7 i I.1 mm Hg. 18.1 t 2.8 mm Hg and 2.9 i 
0.3 literslmin per m*, respectively (p = NS vs. group A). 
Two patients in group A (one in class D and one in class C) 
and three in group B (two in class B and oae in class C) did 
not complete the bmonth follow-up study. In these patients. 
symptoms of heart failure worsened within I to 3 months 
after the run-in period; one patient in group B was lost to 
follow-up evaluation. 
E6ectioa tuogsc, heart sad physicalperfommnce (Table 3). 
In group A. X-ray signs related to extr~~ular lung water 
accumulation (20) were diminished at day 4 and remained so 
during the next 6 months. No response to bronchodilators 
was documented in any patient; an improvement in lung 
function was invariably observed, both at baseline study and 
after bronchodilator inhalation in patients subjected to ultra- 
f&ration. In the same group, a small but significant reduction 
in Left ventricular diastolic diameter occurred after the 
procedure, persisted during the subsequent 30 days and was 
not associated with significant changes in ejection fraction 
(Table 1). In both groups. rest and peak exercise syst:mic 
blood pressure was unchanged during the follow-up period 
(Table 4). There was an improvement in exercise pet-for- 
mance. as suggested by the increase in exercise toleraace, 
time to anaerobic threshold, peak oxygen consumption, 
oxygen consumption at anaerobic threshold. maximal venti- 
lation and tidal volume and reduced peak exercise dead 
space/tidal volume ratio; oxygen pulse was unchanged (Fig. 
1). These changes were present on day 4 and persisted for6 
months in 16 of rhe I8 patients. In the two patients whose 
clinical condition deteriorated during the follow-up period, 
oxygen consumption from day -1 to day 4 increased from 
7.3 to 9.9 mVmin per kgand from 14.4 to 17.3 mYmin per kg. 
respectively. In the group B control patients, none of the 
changes Just reported in group A patients occurred during 
the 6-month follow-up period. 
Inllttenees an plasma mwe+e@&e. Ultrafdtration re- 
duced norepinephrine at rest and shied the relation of 
norepinephrinc to oxygen consumption during exercise 
downward (Table 4, Fig. 2). Peak exercise norepiaepht%e 
plasma levels were similar and within the normal range (13) 
during all tests; however, peak oxygen consumption was 
increased after ultrafiltration. In patients in gulp B. norepi- 
nephtine at rest was unchanged and increased during exer- 
cise to a similar extent each time (Table 4. Fig. 2). Norep% 
nephrine response to orthostatic tilt was attenuated in all 
Group A 
Day-, 3.5 2 0.1 1.6 I 0.1 I10 ? 4 ,I, 24 a3 t 6 8$+7 
w4 3.9 * 0.1’ 3.9 t 0.1’ 127 i 7* 133 2 b* 92 1 6* 94 f 6’ 
Day 30 3.8 * 0.1’ 3.9 f 0.1’ 130’6 131 f 5* 93 f s 95 f 6. 
Davm 1.9 t 0.2’ 4.0 f 0.2. 128 * 8’ ,MZb* 95 f 5. 96 + 5’ 
Day 180 1.9 f 0.1’ 3.9 z cl.** I28 * y I29 f 7’ 95 + 78 97 5 7’ 
ckoup E 
Day -I 3.5 f 0.1 3.6 t 0.1 Ill I4 III 5 6 8527 87 f 9 
WY4 3.4 + 0.1 3620.1 II! 2 5 Ill+6 n3?6 86Z8 
Day 30 3.5 * 0.1 35ro.t 113 2 6 i,5r7 8357 85 * 6 
mYm 3.5 f O-l 3.5 * 0.1 111 25 ll6r7 84*7 8628 
Day IBO 3.4 + 0.1 3.5 t 0.2 LIZ? 5 libt8 83 ? 5 8459 
‘p 4 0.01 venur dry -1. Diflerenccs bctww mea~u~me~ts obhincd at bareline and after ~lbutamal inhalatian we= never si&icant. Dataax RpMtcd 
ss mean value f SEM. PEV, = forced erpnamry vatume (I s): Groups A and B 1% in Table I; hlVV = maximal voluntary ventilation: VC = Vital catracily. 
Table 4. Norepinephrine Plasma Levels and Mean Blood 
Pressure Data 
Ndrqinephrint man Ewd Piassure 
Supinr Rest Peak Exercise 
(pglml) (mm l&l (mm W 
Group A 
Day-1 680 + 170 97 f 3 111 t2 
BY4 562 f 103. 93 + 3 III * 1 
Day 30 474 + 05’ 91 * 2 1c9+3 
DaYW 421 + 99’ 91 * 2 112*4 
Eav Isa 528 z 97’ 91 t 2 IO3 f 3 
h-l fbot 12s 98 + 3 III -4 
DPV 4 
Da; 30 
640 + !78 96+3 112-r5 
658 z 179 9722 113Z6 
hY90 702 f 180 9s * 3 Ill t5 
Da; I80 713 + 176 w*2 112 + 5 
‘p < 0.01 versus day -I. Dila are reported as mean value * SEM. 
Groups A and B BS defined in Table I. 
patients and became greater on days 4 and 90 only in patients 
subjected to ultrafdtration (Fig. 3); in fact, the percent 
increase during orthostatic tilt at days -I, 4 and 90 was 
26.3 + 2.9%, 57.4 2 4.7% (p < 0.01 vs. day -1) and 4.5.8 + 
4.5% (p < 0.01 vs. day -I) in group A and 25.3 ? 3.1%, 
27.2 2 3.l%and 24 2 3.3%(p = NS vs. day -1)ingroop B. 
PIgare 1. Cardiopulmonary exercise test results. *p < O.Wl versus 
day -1. Data arc reported as mean value+ SEM. A, Peak VOL = 
oxygen consumption at peak exercise; Time A.T. = time I” anaer- 
obic :breshold: Tolerance Time = exercise tolerance time: VW 
A.T. = 0xYge.n consumption al anaerobic fhreshold; 0 = group A; 
q = group B. B, 02 Pulse = oxygen pulse at peak exercise; VD/ 
VT = dead space/tidal volume ratio al peak exercise (percent of 
predicted value): VE max = maximal ventilation (percent of pre- 
dicled value): VT max = maximal tidal volume. 
Discussion 
This study shows that subtractioe of approximately 
@IO ml/h of water from plasma to obtain a 50% decrease in 
right atriai pressure in patients with moderate congestive 
heart failure persistently reduces extravascular lung fluid, 
improves lung function and exercise pelfomxmce and mod- 
ifies norepinephrine plasma levels at rest and norepinephrine 
kinetics in a way consistent with a diminished severity of the 
syndrome. 
Hemodynamic effects of ultrafiltration. Ultrafdtration 
lowered cardiac output and ventricular filling pressures, 
possibly as a consequence of reduced intravascular volume. 
Hypovolemia, however, was presumably counteracted by 
extravascular fluid reabsorption through oncotic mecha- 
nisms (30) and, at the level of the long, by a reduction in right 
atrial and pulmonary venous pressure (3L.34). It is docu- 
mented that right atrial pressure influences both lung lymph 
flow (31) and bronchial vein flow (32,33) and pulmonary 
venous pressure aKece~ls rhe bronchial drainage into the 
pulmonary circulation (34). The significant decrease in lung 
congestion after ultrafiltration and the increase in vital 
capacity (Table 3)+ which is another indicator of theintratho- 
racic fluid content (35), are consistent with these interpreta- 
tions. 
Effects of ultrafiltration on pulmonary fun&n. PulmtF 
nary function is likely to become altered in congestive heart 
failure (34) and the lack of response to bronchodilaror 
inhalation suggests that the functional level is stable. The 
relation between left atria1 pressure and small airway resis- 
tance has been interpreted as caused by the influence of 
atria1 pressure on the water content of the lung (37,381. 
‘iherefore, the improved pulmonary function after ultratil- 
tration seems to be attributable to a reduction in the exces- 
sive lung water. allowing decompression of the small air- 
ways (38). The ameliorated respiratory function after 
Figure 2. Norepinephrine (NE) plasma levels al rest (up& posi- 
tion. mouthpiece positioned for ~3 min) and dwing peak exercise. 
Norepinephring values during exercise are ploued versus oxygen 
consumption (VOJ. Data are reported as mean value i SEM. In 
group A (A) but not in group B (II). all noreoinephrine values at rest 
(upright position) and submaximal eaer. .t (25 and 50 WI were 
lowerat dav 4.30.98 and 180 vs. day -I ( .P < 0.W. *P < 0.001 
day 3O;O = day ti. I = &y 18d 
ultrafdtration might be particularly important during exercise 
when heart-lung interdependence is increased (39). 
Effects of ultraflltratinn on exercise nerformance. For an 
appropriate assessment with cardiopulmonary exercise lest- 
ing (24,25,40! of the physical performance of patients with 
conps!ive heart f-lilure. familiarization with the test is 
mandatory (41) and the effects of training skou!d be taken 
into account. In our study, the majority of patients had 
multiple previous experiences with the cardiopulmonary 
exercise test, the drug regimen was kept constant and all 
tests were performed at 10 AM, so that the temporal relation 
between exercise and drug administration was uniform. In 
addition, a training effect was not observed in the control 
patients. It is also unlikely that motivation to perform 
exercise bad an iniluence on our results because oxygen 
consumption at pe& exercise and Ihe anaerobic threshold 
varied similarly, even though only peak exercise measure- 
mems may be affected by the patient’s motivation. The 
clinical condition of two subjects in grump A who showed 
severely compromised exercise capachy at day -I (one in 
clas? D and one in class C) worsened during the follow-up 
period. The improved performance observed at day 4 may 
suggest that these patients possibly eeeded repeated ukr&- 
n-ation as do patients with more advanced congestive heart 
failure (42). In the remaining 16 subjects, the procedure 
persistently augmented oxygen consumption at peak exer- 
cise and the anaerobic threshold, prolonged exercise toler- 
ance time and time to anaerobic threshdd, increased maxi- 
mal ventilation and tidal volume and reduced peak exercise 
dead space/tidal volume ratio (Fig. 1 and 2). All these 
observations are consistent with improved exercise perfor- 
mance and suggest that at peak exercise, more lung paren- 
chyma participated in gas exchange. 
Possible mechau&m$ al her&ii effecIs of t&m. 
Ultrafiltrationdid not modify the pump functionof the heart, 
as reffected by the left ventricular ejection fraction at rest 
(Table 2) and peak exercise oxygen pulse obtained after the 
procedure (Fig. 1). Changes in thoracic X-ray find&s, 
pulmonary function tests, maximal ventilation and tidal 
volume nnd tidal volume/dead space ratio during peak exer- 
cise at day 4 suggest thai one of the mechanisms through 
which subtraction of body fluid by ultrahltration improves 
physical performance might be an influence on the structures 
around the heart, such as the cardiac fossa, lun8 and 
pulmonary vascularure (8.39). The long duration ofbenefits 
from ultrafiltration on physical performaxe, lung water aad 
pulmonary function was unexpected. For various reasons, 
we were OI~$ able !o repeat the measurement of catheter- 
derived variables in a limited number of patients, so La: i! is 
uncertain whether the reduction in right atrial and pulmc- 
nary wedge pressures was persistently associated with the 
described ameliomtion. lJlhafdtration might also have tow- 
ered the impedance to skeletal muscle flow (43) and im- 
pmved perfusion (44) through a reduction in the water 
content of the muscles and vessel walls. However, in our 
patients, this seems an unlikely effect because no patient had 
peripheral edema and blood pressure at rest and during peak 
exercise did not change during the follow-up period. The 
interpretation that the lung was kept dry by diminished 
pressure in the right atrium and pulmonary veins after the 
procedure (allowing effective lung fluid drainage) appears 
more reasonable (31-34). 
An analysis of daily physical activity of the subjects 
during the &month study period was not performed in the 
present study, but no patient was involved in a training 
program. However, the tendency toward a progressive in- 
crease in exercise capacity after ultratiltration (group A) 
might be related to a training effect made possible by the 
improved physical performance observed shortly after the 
procedure. Ultraliltration seems to have reversed a condi- 
tion characterized by elavated tight atrial and pulmonary 
venous pressures and increased lung water and stiffness, 
which in turn augmented respiratory muscle work, tight 
ventricular afterload and the work of the heart against the 
cardiac fossa. Diuretic drugs in doses that prevented fluid 
htention were apparently unable to produce the same ef- 
fects. 
Effects of ukralillralion 011 norepiwphrine levels. In pa- 
tients with congestive heart failure, circulating norepineph- 
tine at rest is generally increased (ll,lZ), its increase during 
orthostatic tilt is blunted (14,15) and, during exercise, for a 
given oxygen consumption, it reaches levels higher than 
those in normal subjects (13). Plasma levels at rest, during 
orthostatic tilt and at submaximal exercise are viewed as 
indexes of the severity of the disease (1 l-15). Ultrafiltration 
reduced norepinephrine at rest and during submaximal work 
loads and shifted the response to or&static tilt toward a 
more favorable pattern. Changes like these have been con- 
sidered to reflect an ameliorated clinical condition (16-19) 
and in our study were associated with increased exercise 
performance. 
Condusions. Subtraction of body fluid by ultrafiltration 
persistently ameliorates the clinical condition of patients 
with moderate congestive heart failure. This effect seems to 
he mainly related to changes trking place within the chest. 
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